Teva Pharmaceutical Industries (FRA:TEV) Earnings Yield %: 4.00% (As of Jul. 12, 2026)


FRA:TEV Teva Pharmaceutical Industries Ltd FRA:TEV
58 GF Score
Price €28.50
GF Value €17.67
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Teva Pharmaceutical Industries Earnings Yield %?

Teva Pharmaceutical Industries FRA:TEV 58 Earnings Yield % is 4.00% as of Jul. 12, 2026. GuruFocus rates FRA:TEV with a GF Score™ of 58/100 and a GF Value™ of €17.67 (Significantly Overvalued). The stock has 4 warning signs investors should review.

The earnings yield is an indication of how much return shareholders' investment in the company earned over the past 12 months. The higher the earnings yield is, the better.

As of today (2026-07-12), the stock price of Teva Pharmaceutical Industries is €28.50. Teva Pharmaceutical Industries's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was €1.14. Therefore, Teva Pharmaceutical Industries's earnings yield of today is 4.00%.

The earnings yield does not consider the growth of the business. A better indicator of the attractiveness of an investment which takes growth into account is the Forward Rate of Return (Yacktman) %. Teva Pharmaceutical Industries's Forward Rate of Return (Yacktman) % for the quarter that ended in Mar. 2026 was 0.00%. The Forward Rate of Return uses the normalized Free Cash Flow of the past five years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.


Teva Pharmaceutical Industries  (FRA:TEV) Earnings Yield % Explanation

If the P/E ratio is an indication of how many years it takes for the company to earn back the stock price shareholders pay to buy the shares, the earnings yield is an indication of how much return shareholders' investment in the company earned over the past 12 months. The higher the earnings yield is, the better.

If a company loses money, the earnings yield is negative. This gives a more straightforward indication that the company is losing money. This is an advantage of using earnings yield instead of the P/E ratio in valuation. For valuation purposes, the P/B Ratio and the P/S Ratio should be used for companies that are losing money.

Like the P/E ratio, the earnings yield can be used to compare investments in different industries. It can even be used to compare the attractiveness of different asset classes such as bonds and cash. Of course, the earnings yield should not be the only factor in deciding which asset classes to invest.

Also similar to the P/E ratio, the earnings yield does not consider the growth of the business. A growing company with the same earnings yield should be more attractive than a company that has the same earnings yield but does not grow.

A better indicator of the attractiveness of an investment which takes growth into account is the Forward Rate of Return (Yacktman) %.

Be Aware

Just like the P/E Ratio, non-recurring items such as selling part of the business, selling a previous investment, etc., can affect earnings yield dramatically. The earning yield is also a poor indication for cyclical companies. When a cyclical stock has a high earnings yield it is usually at the peak of its cycle.


Teva Pharmaceutical Industries Earnings Yield % Related Terms

FRA:TEV
58GF Score
Teva Pharmaceutical Industries Ltd FRA:TEV
Earnings Yield % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Teva Pharmaceutical Industries Earnings Yield % Calculation

Earnings yield is the reciprocal of the P/E Ratio.

Teva Pharmaceutical Industries's Earnings Yield for today is calculated as

Earnings Yield=Earnings per Share (Diluted) (TTM)/Share Price
=1.141/28.50
=4.00 %

Teva Pharmaceutical Industries's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €1.141 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

Earnings Yield=Net Income /Market Cap

The earnings in the calculation is the Trailing Twelve Months earnings.

Frequently Asked Questions Learn more about Earnings Yield % →
What does a Earnings Yield % of 4.00% mean?
Teva Pharmaceutical Industries (FRA:TEV) has a Earnings Yield % of 4.00% as of Jul. 12, 2026. Earnings Yield equals per-share earnings divided by share price. It is the inverse of the price-earnings ratio. View historical data on Teva Pharmaceutical Industries and its competitors.
Is Teva Pharmaceutical Industries' Earnings Yield % too high?
Teva Pharmaceutical Industries' current Earnings Yield % is 4.00%. Overall, Teva Pharmaceutical Industries has a GF Score™ of 58/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Teva Pharmaceutical Industries' Earnings Yield % compare to ZTS and UTHR?
Teva Pharmaceutical Industries' Earnings Yield % of 4.00% can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Earnings Yield % for a Drug Manufacturers company?
A good Earnings Yield % depends on the Drug Manufacturers industry context. However, Earnings Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Earnings Yield % mean?
A high Earnings Yield % can signal that a stock is expensive relative to its fundamentals. Earnings Yield equals per-share earnings divided by share price. It is the inverse of the price-earnings ratio. View historical data on Teva Pharmaceutical Industries and its competitors. Teva Pharmaceutical Industries's current Earnings Yield % is 4.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Teva Pharmaceutical Industries stock overvalued right now?
Based on GuruFocus' analysis, Teva Pharmaceutical Industries (FRA:TEV) is currently considered Significantly Overvalued. The stock's GF Value™ is €17.67, compared to a current price of €28.50 — trading 61.3% above its estimated fair value. The current Earnings Yield % is 4.00%. Teva Pharmaceutical Industries' overall GF Score™ is 58/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Earnings Yield % calculated?
Earnings Yield % is calculated from a company's financial statements. For Teva Pharmaceutical Industries (FRA:TEV), the current Earnings Yield % is 4.00% as of Jul. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Teva Pharmaceutical Industries (FRA:TEV) Overvalued in 2026?

Based on GuruFocus' analysis, Teva Pharmaceutical Industries stock appears to be overvalued. The current stock price of €28.50 is trading 61.3% above its estimated GF Value™ of €17.67. GuruFocus considers Teva Pharmaceutical Industries to be Significantly Overvalued.

Key valuation signals for FRA:TEV:

  • Earnings Yield %: 4.00%
  • GF Value™: €17.67 vs. price of €28.50 (61.3% above fair value)
  • GF Score™: 58/100 with 4 warning signs

No single metric tells the full story. See the FRA:TEV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Teva Pharmaceutical Industries Business Description

Address 124 Dvora HaNevi’a Street, Tel Aviv, ISR, 6944020
Teva Pharmaceutical, based in Israel, is the world's leading generic drug manufacturer. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in two main therapeutic areas: neurology and immunology. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.
58GF Score

Get the complete analysis for FRA:TEV

Earnings Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€28.50
Price
€17.67
GF Value